Praxis Precision Medicines, Inc Announces Pricing of $59 1 Million Public Offering streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BOSTON, June 15, 2023 (GLOBE NEWSWIRE) Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic.
Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Rating) has been given an average recommendation of “Moderate Buy” by the three ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target […]
Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.